Zai Labs will pay up to $176 million for the rights to sell repotrectinib in the Greater China market.
News & Analysis: Turning Point Therapeutics Inc
TPTX earnings call for the period ending March 31, 2020.
Incredibly, they're almost all health stocks, including 7 biotechs, an eye surgery platform, and a medical device company.
TPTX earnings call for the period ending September 30, 2019.
Investing in biotechs is inherently risky. IPOs are too. What does the stock performance of 2019’s biotech IPO class look like so far?